Terminology Service for NFDI4Health
JSON

CDK Inhibitor AT7519

Go to external page http://purl.obolibrary.org/obo/NCIT_C64761

An orally bioavailable small molecule with potential antineoplastic activity. AT7519M selectively binds to and inhibits cyclin dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some types of cancer cells. [ ]

Term info

Label

CDK Inhibitor AT7519

Synonyms
  • AT7519
  • AT7519M
  • CDK Inhibitor AT7519
  • CDK inhibitor AT7519M
  • CDKI AT7519
  • Cyclin-Dependent Kinase Inhibitor AT7519M
Subsets

NCIT_C116978, NCIT_C128784, NCIT_C157711, NCIT_C116977, NCIT_C157712

ALT DEFINITION

A substance being studied in the treatment of some types of cancer. AT7519M blocks enzymes needed for cells to divide. It is a type of cyclin-dependent kinase inhibitor.

CAS Registry

844442-38-2

Chemical Formula

C16H17Cl2N5O2

Display Name

CDKI AT7519

Has Target

http://purl.obolibrary.org/obo/NCIT_C17767

Preferred Name

CDK Inhibitor AT7519

Semantic Type

Pharmacologic Substance, Organic Chemical

UMLS CUI

C1879520

code

C64761